NASDAQ:FEMY Femasys Q3 2025 Earnings Report $2.00 -0.08 (-3.85%) Closing price 04:00 PM EasternExtended Trading$2.00 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Femasys EPS ResultsActual EPS-$2.00Consensus EPS -$2.40Beat/MissBeat by +$0.40One Year Ago EPSN/AFemasys Revenue ResultsActual Revenue$0.73 millionExpected Revenue$1.35 millionBeat/MissMissed by -$620.61 thousandYoY Revenue GrowthN/AFemasys Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time7:00AM ETUpcoming EarningsFemasys' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Femasys Earnings HeadlinesFemasys (NASDAQ:FEMY) Downgraded by Wall Street Zen to "Strong Sell"October 3, 2026 | americanbankingnews.comFemasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s CareSeptember 15, 2026 | finance.yahoo.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 7 at 1:00 AM | Reagan Gold Group (Ad)Femasys Expands Fertility Portfolio Adoption Through Minnesota Women's CareSeptember 15, 2026 | rttnews.comFemasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's CareSeptember 15, 2026 | globenewswire.comFemasys Partners With CapexMD To Expand Access To FemaSeed Fertility PortfolioSeptember 9, 2026 | rttnews.comSee More Femasys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email. Email Address About FemasysFemasys (NASDAQ:FEMY) is a biomedical company focused on developing and commercializing therapies and technologies for women’s health. The company’s products are designed to address reproductive health needs, including contraception and infertility, through minimally invasive procedures intended to be performed in a physician’s office. Femasys’ product portfolio includes FemaSeed, an FDA-cleared intratubal insemination system designed to deliver sperm directly into the fallopian tube during an infertility treatment procedure. The company is also developing FemBloc, a non-surgical, investigational permanent birth-control system intended to provide a hormone-free contraceptive option. FemBloc has not been approved for commercial use in the United States. Headquartered in Atlanta, Georgia, Femasys was founded by Kathy Lee-Sepsick, who serves as the company’s president and chief executive officer. The company primarily develops its products for the U.S. market and has pursued regulatory and commercial opportunities in women’s reproductive health.View Femasys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
